US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg) ...Middle East

STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic...

Hence then, the article about us fda grants priority review to sobi s supplemental biologics licence application sbla for gamifant emapalumab lzsg was published today ( Thursday 27/02/2025 - 10:37 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg) )

Also on site :

• Hollywood mourns loss of beloved makeup artist Jasen Kaplan
• Suspected mountain lion attack in Colorado mountains under investigation
• Person falls to death on Boylston Street on New Year’s Eve